Question 1

What is the analyst consensus rating for NMRA?

Accepted Answer

The analyst consensus rating for NMRA is "Buy" based on 2 analyst recommendations.

Question 2

What is the average price target for NMRA?

Accepted Answer

The average 12-month price target for NMRA is $7.50, representing an upside of 111.9% from the current price of $3.54.

Question 3

What do analyst ratings mean?

Accepted Answer

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

Question 4

What is a price target?

Accepted Answer

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.

Date	Analyst	Firm	Action	Rating	Price Target
Jan 12, 2026	Marc Goodman	Leerink Partners	Initiates	Buy	$8.00
Dec 1, 2025	Brian Abrahams	RBC Capital	Upgrades	Buy	$4.00 → $7.00 +3.00 (75.0%)

Neumora Therapeutics (NMRA) Stock Analyst Forecast

Analyst Consensus Rating

Consensus Rating

Average Price Target

Latest NMRA Analyst Ratings & Recommendations